Revance Therapeutics (RVNC) Shares are Up 25.87%

Revance Therapeutics (RVNC) : Traders are bullish on Revance Therapeutics (RVNC) as it has outperformed the S&P 500 by a wide margin of 13.15% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 25.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 25.87% in the last 1 week, and is up 10.86% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 16.04% and the 50-Day Moving Average is 18.81%.The 200 Day SMA reached 14.63% Revance Therapeutics, Inc. is up 25.11% in the last 3-month period. Year-to-Date the stock performance stands at -51%.


Revance Therapeutics (RVNC) : The consensus price target for Revance Therapeutics (RVNC) is $41.4 for the short term with a standard deviation of $14.05. The most optimist securities analyst among the 5 who monitor the stock believes that the stock can reach $55, however, the pessimist price target for the company is $22.

For the current week, the company shares have a recommendation consensus of Buy. Revance Therapeutics (NASDAQ:RVNC): The stock opened at $14.14 and touched an intraday high of $17 on Friday. During the day, the stock corrected to an intraday low of $14.14, however, the bulls stepped in and pushed the price higher to close in the green at $16.74 with a gain of 18.89% for the day. The total traded volume for the day was 1,274,444. The stock had closed at $16.74 in the previous trading session.

Revance Therapeutics, Inc. is a clinical-stage specialty biopharmaceutical company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through two dose formulations, topical product candidate RT001 and injectable product candidate RT002. RT001 is a non-injectable dose form. RT001 is being studied for aesthetic indications, such as crows feet lines (wrinkles around the eyes) and therapeutic indications, such as hyperhidrosis (excessive sweating). It is in a Phase III development program of RT001 in North America for the treatment of crows feet lines. RT002 is an injectable formulation of botulinum toxin designed to be targeted and longer lasting. RT002 is being studied for aesthetic indications, such as glabellar (frown) lines and therapeutic uses, such as muscle movement disorders.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.